Canada markets open in 8 hours 32 minutes

InMed Pharmaceuticals Inc. (IN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
4.1900-0.0700 (-1.64%)
At close: 03:00PM EST
Full screen
Previous Close4.2600
Open4.2700
Bid4.1300 x N/A
Ask4.4000 x N/A
Day's Range4.1300 - 4.2700
52 Week Range3.3500 - 13.6950
Volume17,035
Avg. Volume21,158
Market Cap33.732M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-1.7500
Earnings DateFeb. 09, 2022 - Feb. 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference

    VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021. Cowen's 4th Annual Cannabis Conference Date: November 29 - December 1, 2021 Management will be available for v

  • ACCESSWIRE

    InMed Pharmaceuticals (INM): Progress Across the Business

    LONDON, UK / ACCESSWIRE / November 17, 2021 / With the recent closing of the BayMedica acquisition, InMed now has a substantially different profile than just a few months ago. The company is now in its commercial stage as BayMedica has been selling cannabichromene (CBC) in bulk.

  • GlobeNewswire

    InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update

    VANCOUVER, British Columbia., Nov. 10, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced financial results for the first quarter of fiscal year 2022 which ended September 30, 2021. “The first quarter of fiscal 2022 saw positive momentum across all of our programs,” says Eric A. Adams, InMed President & CEO. “With the completion of the BayMedica Inc. (